Protara Therapeutics Inc

NASDAQ:TARAUnited States

Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.

Contact Information

Headquarters

345 Park Avenue South, 3Rd FloorNEW YORK, NY, United States 10010

Phone

646-844-0337

Fax

302-655-5049

Executives

Independent Chairman of the Board

Luke Beshar

President, Chief Executive Officer, Director

Jesse Shefferman

Chief Financial Officer

Patrick Fabbio

Chief Scientific Operations Officer

Jacqueline Zummo

Controller

Hannah Fry